This continuing medical education activity is supported through educational grants from Regeneron Pharmaceuticals, Inc. and Carl Zeiss Meditec, Inc.
Upon completion of this activity, the participant should be able to:
Identify and Implement algorithms, decision-making tools, and patient communication approaches that can be used to determine the most appropriate treatment for the patient.
Identify opportunities to advocate against prior authorizations and step policies and appeal them.
Identify the potential impact of the Drug Quality and Security Act and opportunities to advocate for continued access to compounded ophthalmologic drugs.
Describe the impact of MACRA on ophthalmology and its potential impact on the prescribing of anti-VEGF agents.
Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Evolve Medical Education LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The following fellows/faculty members have the following financial relationships with commercial interests:
Tara McCannel, MD, PhD; D. Wilkin Parke III, M.D.; Dimitra Skondra, MD, PhD; Camila Ventura, MD, PhD; Christopher Adam, MD; Nicolas Crim, MD; Avner Hostovsky, MD; Rehan Hussain, MD; Talia Kaden, MD; Steven Saraf, MD; Sidney Schechet, MD; Peter Tang, MD, PhD, have no financial relationships with commercial interests.
Aleksandra V. Rachitskaya, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Allergan, & Carl Zeiss Meditec.
Anton Orlin, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Carl Zeiss Meditec.
Pravin U. Dugel, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/ Advisory Board Member: Abbott/AMO, Acucela, Aerie Pharmaceuticals, Aerpio, Alcon, Alimera Sciences, Allergan, Amgen, Annidis, ArticDX, Avalanche, Bausch & Lomb, Boehringer Ingelheim, ByeOnics, Carl Zeiss Meditec, Chengdu Kanghong Biotechnology, Clearside Biomedical, CDR-Life, Inc., Digisight, Dose Medical, Genentech, Graybug Vision, Irenix, Kodiak Sciences, Lutronic, Lux BioScience, Macusight, NeoVista, Neurotech, Novartis, Oculis, Ophthotech, Omeros, Opthea, Optovue, ORA, Orbis International, Panoptica, Pentavision, pSivida Corporation, QLT, Inc., Regeneron, Roche, Santen, SciFluor Life Sciences, Shire Human Genetics, Spark Therapeutics, Stealth Biotherapeutics, Thrombogenetics, Topcon, and TrueVision, Stock/Shareholder: Aerpio, Alimera, Annidis, ArctixDx, Clearside Biomedical, Digisight, Irenix, Ophthotech and PanOptica.
Phillip Ferrone, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Genentech; Grant/Research Support: Genentech; Samsung; Stock/Shareholder: ArcticDx.
Editorial Support Disclosures, Susan Gallagher-Pecha, Director of client services and project management, Evolve, has no financial relationships with commercial interests.